2019 American Transplant Congress
De Novo Donor Specific Antibody and Panel Reactivity Antibody Are Critical Risk Factors for Antibody Mediated Rejection of Kidney Allograft after Simultaneous Liver-Kidney Transplantation (a Single Center Study Using Surveillance Renal Biopsies)
1Avalon Medical University, Willemstad, Netherlands Antilles, 2Cleveland Clinic, Cleveland, OH
*Purpose: Even though the liver may provide immunologic protection to the kidney from hyperacute rejection, previous publications suggest this protective effect is not sufficient to…2019 American Transplant Congress
Effect of Everolimus with Reduced-Exposure Tacrolimus and Early Steroid Elimination in Pediatric Kidney Transplant Recipients: 36-Month Outcomes from the CRADLE Study
1A2314 Study Group, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland
*Purpose: To compare 36-month (M) efficacy and safety outcomes of an everolimus+reduced-exposure tacrolimus (EVR+rTAC)+steroids (CS) withdrawal regimen vs mycophenolate mofetil+standard-exposure TAC (MMF+sTAC)+CS in pediatric kidney…2019 American Transplant Congress
Hard-to-Place Kidney Offers: Through the Lens of the United Network for Organ Sharing Organ Center
United Network for Organ Sharing, Richmond, VA
*Purpose: In 2016, the rate of deceased donor kidney discard continued to increase to 20%. It is well documented that multiple factors contribute to lower…2019 American Transplant Congress
Kidney Xenotransplantation from Genetically Engineered Pigs to Baboons with FDA-Approved Immunosuppressive Therapy
*Purpose: Genetically-engineered pigs might present a solution to the critical shortage of organs for clinical transplantation. The aims of this study were to evaluate the…2019 American Transplant Congress
Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients with Interstitial Fibrosis and Tubular Atrophy
*Purpose: Prior studies on the conversion of tacrolimus (Calcineurin Inhibitor; CNI) to belatacept have been limited in scope due to either the absence of, post-conversion…2019 American Transplant Congress
Successful Use of Hizentra to Address BK Viremia in Pediatric Transplant Population
Pediatric Nephrology, Saint Louis University, Saint Louis, MO
*Purpose: BK viremia is an important problem in the pediatric renal transplant population leading to increased risk for viral associated nephropathy in the transplant. Early…2019 American Transplant Congress
Prophylactic Use of Eculizumab in Patients at High Risk of Post-Transplant aHUS Recurrence Improves Graft Outcomes
On behalf of the French aHUS Group, France, France
*Purpose: Eculizumab has revolutionized the management of atypical Hemolytic Uremic Syndrome (aHUS). In 2012, the French aHUS Study Group issued recommendations to advocate the prophylactic…2019 American Transplant Congress
Quantifying Differential Infection Risks in HLA- and/or ABO- Incompatible Kidney Transplant Recipients
1Johns Hopkins, Baltimore, MD, 2New York University, New York, NY
*Purpose: Desensitization has enabled kidney transplantation across HLA-and/or ABO barriers and has conferred survival benefit to patients who lack compatible living donors (CLDKT). However, due…2019 American Transplant Congress
Reduction In Early Readmission In Kidney Recipients – Outcomes At One Year With Standardized Intensive Follow Up
Glickman Urological and Kidney Institute CCF, Cleveland, OH
*Purpose: Kidney transplant recipients often experience frequent ED visits and high early hospital readmission (EHR) rates (within 30 days). We sought to decrease our preventable…2019 American Transplant Congress
Predictors of Response to Intravenous Immunoglobulin for Treatment of Polyoma Nephropathy
Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: BK nephropathy is an important cause of allograft dysfunction or loss. IVIg is hypothesized to be effective by providing passive immunity to BK virus…
- « Previous Page
- 1
- …
- 192
- 193
- 194
- 195
- 196
- …
- 531
- Next Page »